US Stock MarketDetailed Quotes
ELYM Eliem Therapeutics
- 8.000
- +0.700+9.59%
Trading Jul 22 13:36 ET
534.28MMarket Cap-15384P/E (TTM)
8.300High7.515Low534.85KVolume7.750Open7.300Pre Close4.23MTurnover2.07%Turnover RatioLossP/E (Static)66.79MShares11.55052wk High5.02P/B206.68MFloat Cap2.35052wk Low--Dividend TTM25.84MShs Float29.690Historical High--Div YieldTTM10.75%Amplitude2.210Historical Low7.913Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Eliem Therapeutics Stock Forum
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
Eliem Therapeutics has completed its acquisition of Tenet Medicines and a concurrent $120 million private placement. The company plans to advance TNT119, an anti-CD19 antibody aimed at treating various autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. With the acquisition, Eli...
Onconova Tx merger w/ Trawsfynydd Tx
$Aditxt(ADTX.US)$ to acquire Appili Tx
TuHURA Biosciences merger w/ $Kintara Therapeutics(KTRA.US)$
$Johnson & Johnson(JNJ.US)$ to acquire $ShockWave Medical(SWAV.US)$
$Vertex Pharmaceuticals(VRTX.US)$ to acquire $Alpine Immune(ALPN.US)$
$Century Therapeutics(IPSC.US)$ to acquire Clade Tx
$Eliem Therapeutics(ELYM.US)$ to acquire Tenet Med.
$Incyte(INCY.US)$ to acquire Escient Pharm.
ONO Pharm to acquire $Deciphera Pharmaceuticals(DCPH.US)$
...
In an ambitious move that is set to redefine the landscape of the biopharmaceutical industry, Eliem Therapeutics, Inc. has officially announced its agreement to acquire Tenet Medicines, Inc. Alongside this acquisition, Eliem has also unveiled plans for a concurrent $120 million private placement, marking a significant financial investme...
📊⚡️📊
NEWS
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
Eliem Therapeutics, Inc. (ELYM) announces the acquisition of Tenet Medicines, Inc., focusing on advancing TNT119, an anti-CD19 antibody, for autoimmune diseases. The combined company expects to have $210 million in cash, including $120 million from a private placement. The acquisition aims to fund operations until 2027 and achieve key clinical miles...
No comment yet